Eli Lilly Raises Full-Year Revenue Outlook Driven by Strong Weight-Loss Drug Demand
Eli Lilly reported third-quarter financial results that exceeded analyst expectations, primarily fueled by robust demand for its blockbuster weight-loss and diabetes medications, Mounjaro and Zepbound. Following the report, the company raised its full-year 2026 revenue outlook to reflect sustained market momentum in the metabolic health sector. In response to the news, Eli Lilly shares rose 4% in premarket trading. The strong performance highlights the growing dominance of Lilly's incretin-based therapies and underscores the massive scale of the global obesity drug market, which continues to drive significant valuation shifts for major pharmaceutical players.
Topics: earnings beat pharmaceuticals revenue guidance weight-loss drugs
Read the full article at Seeking Alpha
Part of the story Mobileye Raises Full-Year Revenue Outlook Amid Growth in ADAS and Chinese Vehicle Exports (7 articles)